{
  "id": "5e64f1921af46fc130000018",
  "type": "yesno",
  "question": "Is there a vaccine for rotavirus?",
  "ideal_answer": "Effectiveness of rotavirus pentavalent vaccine  rotavirus pentavalent vaccine (RotaTeq(r)) as a sole vaccine",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/9015114",
    "http://www.ncbi.nlm.nih.gov/pubmed/2851185",
    "http://www.ncbi.nlm.nih.gov/pubmed/7707626",
    "http://www.ncbi.nlm.nih.gov/pubmed/22796685",
    "http://www.ncbi.nlm.nih.gov/pubmed/16397431",
    "http://www.ncbi.nlm.nih.gov/pubmed/8920706",
    "http://www.ncbi.nlm.nih.gov/pubmed/24422678",
    "http://www.ncbi.nlm.nih.gov/pubmed/28442435",
    "http://www.ncbi.nlm.nih.gov/pubmed/27443593",
    "http://www.ncbi.nlm.nih.gov/pubmed/19995190",
    "http://www.ncbi.nlm.nih.gov/pubmed/9949951",
    "http://www.ncbi.nlm.nih.gov/pubmed/22702319",
    "http://www.ncbi.nlm.nih.gov/pubmed/22431803",
    "http://www.ncbi.nlm.nih.gov/pubmed/22119590",
    "http://www.ncbi.nlm.nih.gov/pubmed/22423021",
    "http://www.ncbi.nlm.nih.gov/pubmed/26263200",
    "http://www.ncbi.nlm.nih.gov/pubmed/19931717",
    "http://www.ncbi.nlm.nih.gov/pubmed/21504245",
    "http://www.ncbi.nlm.nih.gov/pubmed/8752295",
    "http://www.ncbi.nlm.nih.gov/pubmed/11389295",
    "http://www.ncbi.nlm.nih.gov/pubmed/27522178",
    "http://www.ncbi.nlm.nih.gov/pubmed/25680314",
    "http://www.ncbi.nlm.nih.gov/pubmed/20661105",
    "http://www.ncbi.nlm.nih.gov/pubmed/30046133",
    "http://www.ncbi.nlm.nih.gov/pubmed/28340179",
    "http://www.ncbi.nlm.nih.gov/pubmed/29102168",
    "http://www.ncbi.nlm.nih.gov/pubmed/15502699",
    "http://www.ncbi.nlm.nih.gov/pubmed/31023829",
    "http://www.ncbi.nlm.nih.gov/pubmed/28369477"
  ],
  "snippets": [
    {
      "text": "Safety and Immunogenicity of Pentavalent Rotavirus Vaccine (RV5)",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28340179",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "This study compares the safety and immunogenicity of pentavalent rotavirus vaccine (RV5)",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28340179",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Effectiveness of rotavirus pentavalent vaccine",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28442435",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": " rotavirus pentavalent vaccine (RotaTeq\u00ae) as a sole vaccine",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28442435",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We describe rotavirus vaccine coverage and missed opportunities for rotavirus vaccination.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31023829",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS\n\nAddressing missed opportunities for rotavirus vaccination is essential to achieving the 80% rotavirus vaccine coverage target outlined by Healthy People 2020.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31023829",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Complete rotavirus vaccine coverage could be improved to 81% if all missed opportunities within the ACIP-recommended schedule were addressed.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31023829",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "RESULTS\n\nThe national coverage for rotavirus vaccine achieved a year after the introduction was 89% for one dose and 82% for two doses, respectively.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27522178",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS\n\nNorway achieved a high national coverage and excellent adherence with the strict age limits for rotavirus vaccine administration during the first year of introduction, indicating robustness of the national immunisation programme.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27522178",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Upper age limit recommendations for rotavirus vaccine administration contributed to suboptimal vaccination coverage.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26263200",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Catching-up with pentavalent vaccine: Exploring reasons behind lower rotavirus vaccine coverage in El Salvador.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26263200",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "US Rotavirus Vaccine Efficacy Group.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/7707626",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "We describe rotavirus vaccine coverage and missed opportunities for rotavirus vaccination.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31023829",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Rotavirus vaccines: a story of success.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25680314",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Clinical and immunological studies of rotavirus vaccines.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/2851185",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Impact of rotavirus vaccine on rotavirus diarrhoea in countries of East and Southern Africa.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29102168",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Rotavirus diarrheal episodes were identified by ELISA.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/8920706",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The decrease in rotavirus positivity was inversely related to increase in rotavirus vaccine coverage showing impact of rotavirus vaccines.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29102168",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We described trends in rotavirus positivity among tested stool samples before and after rotavirus vaccine introduction.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29102168",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The RIT 4237 bovine rotavirus vaccine has served as a useful model for rotavirus vaccination, but the vaccine will not be further developed or tested.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/2851185",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Only the RRV vaccine induced a low level of protection against rotavirus diarrhea mainly of serotype G1 specificity.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/8920706",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "It is recommended that new rotavirus vaccine candidates be developed at cheaper price to speed up the introduction of rotavirus immunization in the developing world in general.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22119590",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Review of rotavirus vaccine trials in Finland.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/8752295",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Risk of intussusception after monovalent rotavirus vaccination.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24422678",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Rotavirus vaccines are underused compared with other routine vaccines.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31023829",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "With rotavirus vaccines now available globally , it will be useful to assemble the available evidence on the epidemiology and burden of rotavirus gastroenteritis in India , in order to weigh the urgency of introducing a vaccine to help control rotavirus disease",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22796685",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Is there evidence that rotavirus vaccines are effective in preventing acute gastroenteritis complications such as dehydration and hospitalization",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22423021",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "With the introduction of new rotavirus vaccines in sight , rotavirus gastroenteritis may be regarded as the single most frequent vaccine-preventable disease among children in the EU",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/16397431",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "With the recent introduction of the two rotavirus vaccines , RotaTeq and Rotarix , in many countries , it appears that the total number of hospitalizations due to rotavirus infections is being reduced , at least in developed countries that implemented a universal immunization program",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19995190",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Change in rotavirus epidemiology in northeast Florida after the introduction of rotavirus vaccine",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20661105",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "With the recent postlicensure identification of an increased risk of intussusception with rotavirus vaccine , the 14 Latin American countries currently using rotavirus vaccine must now weigh the health benefits versus risks to assess whether to continue vaccination",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22431803",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Impact of rotavirus vaccines on rotavirus disease",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22702319",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "With safe and efficacious rotavirus vaccines now on the verge of widespread adoption , researchers can be vital advocates for their uptake into routine immunization programs",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19931717",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Rotavirus vaccine RIX4414 (Rotarix\u2122): a pharmacoeconomic review of its use in the prevention of rotavirus gastroenteritis in developed countries.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21504245",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "In addition, various naturalistic studies have demonstrated 'real-world' effectiveness after the introduction of widespread rotavirus vaccination programmes in the community setting.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21504245",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The monovalent rotavirus vaccine RIX4414 (Rotarix\u2122) is administered as a two-dose oral series in infants and has demonstrated protective efficacy against RVGE in clinical trials conducted in developed countries.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21504245",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Numerous cost-effectiveness analyses have been conducted in developed countries in which a universal rotavirus vaccination programme using RIX4414 was compared with no universal rotavirus vaccination programme.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21504245",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "It is also difficult to draw conclusions regarding the cost effectiveness of rotavirus vaccine RIX4414 relative to that of the pentavalent rotavirus vaccine, which is administered as a three-dose oral series.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21504245",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Although indirect comparisons in cost-effectiveness analyses indicate that RIX4414 provided more favourable incremental cost-effectiveness ratios when each vaccine was compared with no universal rotavirus vaccination programme, results were generally sensitive to vaccine costs.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21504245",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "A rotavirus vaccine for prophylaxis of infants against rotavirus gastroenteritis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/15502699",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "A live attenuated monovalent rotavirus vaccine (Rotarix) containing human rotavirus strain RIX4414 of G1P1A P[8] specificity is being developed to meet the global need.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/15502699",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Rotarix significantly reduced rotavirus gastroenteritis episodes and rotavirus-related hospitalizations in vaccinated infants compared with placebo recipients (P < 0.05).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/15502699",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We describe the intussusception epidemiology prior to rotavirus vaccine, temporal association of intussusception cases to administration of rotavirus vaccine, and estimate the additional number of intussusception cases that may be associated with rotavirus vaccine.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30046133",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Epidemiology of intussusception before and after rotavirus vaccine introduction in Fiji.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30046133",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "In 2012, Fiji introduced rotavirus vaccine (Rotarix, GSK) into the national immunisation schedule.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30046133",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Four trials of RIT 4237 bovine rotavirus vaccine, one trial of group A RRV-1 rhesus rotavirus vaccine, and one trial of rhesus-human reassortant rotavirus vaccines D x RRV and DS1 x RRV were carried out between 1983-1989.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/9015114",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Problems associated with the use of any oral rotavirus vaccine include acid lability of the vaccine virus, which requires buffering, and a slight but significant interference of oral poliovirus vaccine with the uptake of rotavirus vaccine.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/9015114",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In the near future, oral heterologous rotavirus vaccines may be available for prevention of severe rotavirus gastroenteritis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/9015114",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "There was no apparent difference between bovine and rhesus-based rotavirus vaccines in the protective efficacy against severe rotavirus gastroenteritis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/9015114",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Efficacy studies of this vaccine in 6-12 month-old children gave results characteristic of the performance of oral rotavirus vaccines in general: 58% protective efficacy against any rotavirus gastroenteritis and 82% against \"clinically significant\" gastroenteritis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/9015114",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Live oral rotavirus vaccine strain RIT 4237, derived from group A bovine rotavirus NCDV, was given to human volunteers in Tampere, Finland in 1982.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/9015114",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Targeted efforts to evaluate indirect effects of rotavirus vaccine in low income countries are required to understand the total impact of rotavirus vaccine on the global burden of rotavirus disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27443593",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Widespread introduction of rotavirus vaccines has led to major reductions in the burden of rotavirus gastroenteritis worldwide.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27443593",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "While rotavirus vaccine indirect effects have been demonstrated in high and middle income countries, there are very little data from low income countries where force of infection, population structures and vaccine schedules differ.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27443593",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Measuring indirect effects of rotavirus vaccine in low income countries.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27443593",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Intussusception among recipients of rotavirus vaccine: reports to the vaccine adverse event reporting system.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/11389295",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Rotavirus vaccine was licensed on August 31, 1998, and subsequently recommended for routine use among infants.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/11389295",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "To describe the cases of intussusception among rotavirus vaccine recipients reported to the Vaccine Adverse Event Reporting System from October 1998 through December 1999.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/11389295",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Infants vaccinated with rotavirus vaccine in the United States.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/11389295",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "There were 98 confirmed cases of intussusception after vaccination with rotavirus vaccine reported to the Vaccine Adverse Event Reporting System; 60 of these developed intussusception within 1 week after vaccination.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/11389295",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Using a passive surveillance system for vaccine adverse events, we observed at least a fourfold increase over the expected number of intussusception cases occurring within 1 week of receipt of rotavirus vaccine.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/11389295",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Other studies were initiated to further define the relationship between rotavirus vaccine and intussusception.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/11389295",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In light of these and other data, the rotavirus vaccine manufacturer voluntarily removed its product from the market, and the recommendation for routine use of rotavirus vaccine among US infants has been withdrawn.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/11389295",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "To review the biology, immunology, and virology of rotavirus infections and describe the efforts towards the construction of vaccines using human and animal rotaviruses.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/9949951",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In August 1998 the Food and Drug Administration in the United States approved the licensure of a rotavirus vaccine.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/9949951",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "Yes"
}